Harripaul, Ricardo
Morini, Elisabetta
Salani, Monica
Logan, Emily
Kirchner, Emily
Bolduc, Jessica
Chekuri, Anil
Currall, Benjamin
Yadav, Rachita
Erdin, Serkan
Talkowski, Michael E.
Gao, Dadi
Slaugenhaupt, Susan
Funding for this research was provided by:
National Institutes of Health (R37NS095640)
Article History
Received: 31 October 2023
Accepted: 31 December 2023
First Online: 4 January 2024
Change Date: 2 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-60576-8
Competing interests
: The authors declare no competing interests. Susan A. Slaugenhaupt is a paid consultant to PTC Therapeutics and is an inventor on several U.S. and foreign patents and patent applications assigned to the Massachusetts General Hospital, including U.S Patents 8,729,025 and 9,265,766, both entitled “ for altering mRNA splicing and treating familial dysautonomia by administering benzyladenine,” filed on August 31, 2012 and May 19, 2014 and related to use of kinetin; and U.S. Patent 10,675,475 entitled, “Compounds for improving mRNA splicing” filed on July 14, 2017 and related to use of BPN-15477. Elisabetta Morini, Dadi Gao, Michael E. Talkowski and Susan A. Slaugenhaupt are inventors on an International Patent Application Number PCT/US2021/012103, assigned to Massachusetts General Hospital and entitled “RNA Splicing Modulation” related to use of BPN-15477 in modulating splicing.